Humana Inc vs Monster Beverage Corp — how do they compare? Humana Inc trades at $444.98 (market cap $47.61B), while Monster Beverage Corp trades at $43.6 (market cap $84.00B). The key difference: Monster Beverage Corp is the larger of the two by market cap, and Humana Inc pays a 0.89% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Monster Beverage Corp for 72 Days on average.
| HUM | MNST | |
|---|---|---|
Market Cap | $47.61B | $84.00B |
Volume | 1,827,332 | 8,371,981 |
Sector | Health | Consumer Staples |
52-Week High | $409.85 | $49.97 |
52-Week Low | $163.67 | $33.16 |
Typical Hold Time | 53 Days | 72 Days |
Enterprise Value | $54.97B | $82.30B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Monster Beverage (MNST) trades at $42.88, down 0.86% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported robust Q2 2026 earnings, beating estimates with $0.30 EPS, and maintains impressive profitability metrics including 55.55% gross margin and 23.08% net income margin. Recent news highlights Monster's debt-free balance sheet and international expansion driving 35% overseas sales growth.
While valuation multiples appear elevated (P/E 39.7, P/S 9.18), Monster's consistent earnings beats and analyst consensus price target of $98.22 suggest significant upside potential. Key risks include regulatory challenges in international markets and competitive pressures, but the company's strong cash flow generation and market position support long-term growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →